Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Mexican Stock Exchange  >  Genomma Lab Internacional SAB de CV    LAB B   MX01LA010006

GENOMMA LAB INTERNACIONAL SAB DE CV

(LAB B)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Mexican Stock Exchange
03/15/2019 03/19/2019 03/20/2019 03/21/2019 03/22/2019 Date
12.05(c) 12.09(c) 12.56(c) 12.54(c) 12.52 Last
3 726 722 6 098 917 3 401 727 2 791 305 773 498 Volume
-2.19% +0.33% +3.89% -0.16% -0.16% Change
More quotes
Financials (MXN)
Sales 2019 12 850 M
EBIT 2019 2 699 M
Net income 2019 1 361 M
Debt 2019 3 473 M
Yield 2019 3,21%
Sales 2020 13 723 M
EBIT 2020 3 121 M
Net income 2020 1 548 M
Debt 2020 3 448 M
Yield 2020 -
P/E ratio 2019 8,40
P/E ratio 2020 7,16
EV / Sales2019 1,29x
EV / Sales2020 1,20x
Capitalization 13 048 M
More Financials
Company
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such... 
Sector
Pharmaceuticals
Calendar
04/25Earnings Release
More about the company
Surperformance© ratings of Genomma Lab Internacional
Trading Rating : Investor Rating :
More Ratings
Latest news on GENOMMA LAB INTERNACIONAL
2018GENOMMA LAB INTERNACIONAL DE CV : IFC and IDB Invest Will Provide a US$100 Milli..
AQ
2013GENOMMA LAB INTERNACIONAL SAB DE CV : Anuncio Wal-mart - TCP
PU
2013GENOMMA LAB INTERNACIONAL SAB DE CV : quaterly earnings release
2013Mexico's Genomma Lab to Sell Products in U.S. Wal-Mart Stores
DJ
2012GENOMMA LAB INTERNACIONAL SAB DE CV : GLI Secures Committed Financing to acquire..
PU
2011GENOMMA LAB : Termination of XL-3 License Agreement
PU
More news
Analyst Recommendations on GENOMMA LAB INTERNACIONAL
More recommendations
Sector news : Pharmaceuticals - NEC
03:58aASTRAZENECA : EU approves AstraZeneca's drug for adjunct use in Type-1 diabetes
RE
03:28aASTRAZENECA : Gets European Approval for Forxiga in Type-1 Diabetes Treatment
DJ
03/24BAYER : CEO says his team retains backing of supervisory board
RE
03/22FDA Rejects Oral Treatment for Type 1 Diabetes - Update
DJ
03/22ALLERGAN : promises independent board chair in next leadership change
RE
More sector news : Pharmaceuticals - NEC
Chart GENOMMA LAB INTERNACIONAL SAB DE CV
Duration : Period :
Genomma Lab Internacional SAB de CV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENOMMA LAB INTERNACIONAL
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 18,8  MXN
Spread / Average Target 51%
EPS Revisions
Managers
NameTitle
Jorge Luis Brake Valderrama Chief Executive Officer
Rodrigo Alonso Herrera Aspra Chairman
Antonio Zamora Galland Vice President-Administration & Finance
Juan Alonso Independent Director
Sabrina Lucila Herrera Aspra Director
Sector and Competitors
1st jan.Capitalization (M$)
GENOMMA LAB INTERNACIONAL SAB DE CV7.28%684
JOHNSON & JOHNSON6.09%364 560
NOVARTIS10.71%239 248
ROCHE HOLDING LTD.10.68%233 745
PFIZER-4.12%232 343
MERCK AND COMPANY7.70%212 409